Why Screen as Mixtures? In many cases, it is much more efficient to screen as mixtures because it pares down the dataset to a manageable range. One uses screening mixtures by soaking the crystal in a cocktail with multiple ligands. The secret to designing the proper mixture is to ensure that each ligand in the cocktail is differentiable from the other ligands, even at low resolutions. Express-Zen-Core288™ has a very high shape diversity, making it possible to group into shape

What is Crystallographic Screening? Crystallographic screening is a method used to detect ligands that bind to a target protein. What makes this metod special is that it also provides structural data about the binding location and interactions between the ligand and protein. The crystal itself has the protein molecules lined up in an ordered array with large solvent channels so that ligands can soak in and bind to sites on the crystallized protein. This method is exceptionall

PART 1: What is Chemical Diversity? This is the first in a three-part series discussing chemical diversity. In Part 1, we introduce the concept of diversity in the context of fragment screening libraries. How does one understand Chemical Diversity? Merriam-Webster dictionary defines diversity as: “an instance of being composed of differing elements or qualities". In the context of screening libraries, we refer to chemical diversity as the diversity of the chemical composition

The "Guideline of Two" Over the past decade, a number of rules and calculated metrics have arisen in drug discovery. In particular, the Rule of Three (RO3) is most commonly used as a filter to generate a "fragment library" from a larger compound collection. However: Rules evolve over time to reflect data and experiences Issues can arise from universally applying rules to all situations Emerging data has shown that a simple filter of compound libraries to generate a "RO3 frag

As fragment screening continues to grow in popularity and establish itself as an integral part of discovery research, the emergence of more and more compounds added to fragment library collections seems to grow exponentially. What once was an efficient means of effectively screening a target to provide information about its drugability or identify the unique building blocks of a clinical candidate, has now become diluted in a pool of tens or hundreds of thousands of compounds

Zenobia Therapeutics was founded in 2008 by Drs Vicki Nienaber and Robert Meadows. Zenobia’s founders are pioneers in the field of fragment-based lead discovery (FBLD) contributing to the model NMR screening paradigm, SARbyNMR (1,2) and inventing the first crystallographic screening method, CrystaLead (3). Recognizing that diseases of the CNS are a significant unmet medical need, Zenobia Therapeutics quickly adapted the strengths of FBLD to address one of the biggest challeng

Welcome to our new blog. Here, we will be sharing thoughts and opinions based upon our 20-30 years of experience in fragment screening and structural biology. We will share data we have generated and significant findings that we feel apply to the structural biology and fragment screening field. We welcome your comments on the utility of our products, challenges you face in your research and your opionions on the field in general. Zenobia Fragments became an official entity i